PROF · Profound Medical Corp. · Insider Trading
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-05-16 | Menawat Arun Swarup |
Director, CEO |
Buy↑
Filing footnotes — Common Shares (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.70 to $4.78, inclusive. The reporting person undertakes to provide to Profound Medical Corp., any security holder of Profound Medical Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
Common Shares
|
12,027 |
| 2025-05-15 | Menawat Arun Swarup |
Director, CEO |
Buy↑
Filing footnotes — Common Shares (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.35, inclusive. The reporting person undertakes to provide to Profound Medical Corp., any security holder of Profound Medical Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. |
Common Shares
|
10,003 |